• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

综合上皮性输卵管-卵巢癌风险预测模型,纳入遗传和流行病学风险因素。

Comprehensive epithelial tubo-ovarian cancer risk prediction model incorporating genetic and epidemiological risk factors.

机构信息

Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.

Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK.

出版信息

J Med Genet. 2022 Jul;59(7):632-643. doi: 10.1136/jmedgenet-2021-107904. Epub 2021 Nov 29.

DOI:10.1136/jmedgenet-2021-107904
PMID:34844974
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9252860/
Abstract

BACKGROUND

Epithelial tubo-ovarian cancer (EOC) has high mortality partly due to late diagnosis. Prevention is available but may be associated with adverse effects. A multifactorial risk model based on known genetic and epidemiological risk factors (RFs) for EOC can help identify women at higher risk who could benefit from targeted screening and prevention.

METHODS

We developed a multifactorial EOC risk model for women of European ancestry incorporating the effects of pathogenic variants (PVs) in , , , and , a Polygenic Risk Score (PRS) of arbitrary size, the effects of RFs and explicit family history (FH) using a synthetic model approach. The PRS, PV and RFs were assumed to act multiplicatively.

RESULTS

Based on a currently available PRS for EOC that explains 5% of the EOC polygenic variance, the estimated lifetime risks under the multifactorial model in the general population vary from 0.5% to 4.6% for the first to 99th percentiles of the EOC risk distribution. The corresponding range for women with an affected first-degree relative is 1.9%-10.3%. Based on the combined risk distribution, 33% of PV carriers are expected to have a lifetime EOC risk of less than 10%. RFs provided the widest distribution, followed by the PRS. In an independent partial model validation, absolute and relative 5-year risks were well calibrated in quintiles of predicted risk.

CONCLUSION

This multifactorial risk model can facilitate stratification, in particular among women with FH of cancer and/or moderate-risk and high-risk PVs. The model is available via the CanRisk Tool (www.canrisk.org).

摘要

背景

上皮性输卵管卵巢癌(EOC)死亡率高,部分原因是诊断较晚。目前已有预防措施,但可能会伴随不良反应。基于上皮性输卵管卵巢癌已知的遗传和流行病学风险因素(RFs)的多因素风险模型,可以帮助确定处于高风险的女性,她们可能受益于靶向筛查和预防。

方法

我们为欧洲血统的女性开发了一种上皮性输卵管卵巢癌多因素风险模型,纳入了 、 、 、 和 致病性变异(PVs)的影响、任意大小的多基因风险评分(PRS)、RFs 的影响以及通过合成模型方法明确的家族史(FH)。PRS、PV 和 RFs 被假定为相乘作用。

结果

基于目前可用于上皮性输卵管卵巢癌的 PRS,它解释了上皮性输卵管卵巢癌多基因变异的 5%,在一般人群中,多因素模型下的终生风险在上皮性输卵管卵巢癌风险分布的第 1 到 99 百分位从 0.5%到 4.6%不等。对于有一级亲属受影响的女性,对应的范围为 1.9%-10.3%。基于综合风险分布,预计 33%的 PV 携带者的终生上皮性输卵管卵巢癌风险低于 10%。RFs 提供了最广泛的分布,其次是 PRS。在独立的部分模型验证中,五分位预测风险的绝对和相对 5 年风险校准良好。

结论

这种多因素风险模型可以促进分层,特别是在有癌症家族史和/或中等风险和高风险 PVs 的女性中。该模型可通过 CanRisk 工具(www.canrisk.org)获得。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e8b5/9252860/167497c9dce3/jmedgenet-2021-107904f04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e8b5/9252860/3cf9c51d7e83/jmedgenet-2021-107904f01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e8b5/9252860/4f05996167a6/jmedgenet-2021-107904f02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e8b5/9252860/83e72c20ec1e/jmedgenet-2021-107904f03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e8b5/9252860/167497c9dce3/jmedgenet-2021-107904f04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e8b5/9252860/3cf9c51d7e83/jmedgenet-2021-107904f01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e8b5/9252860/4f05996167a6/jmedgenet-2021-107904f02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e8b5/9252860/83e72c20ec1e/jmedgenet-2021-107904f03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e8b5/9252860/167497c9dce3/jmedgenet-2021-107904f04.jpg

相似文献

1
Comprehensive epithelial tubo-ovarian cancer risk prediction model incorporating genetic and epidemiological risk factors.综合上皮性输卵管-卵巢癌风险预测模型,纳入遗传和流行病学风险因素。
J Med Genet. 2022 Jul;59(7):632-643. doi: 10.1136/jmedgenet-2021-107904. Epub 2021 Nov 29.
2
Validation of the BOADICEA model for epithelial tubo-ovarian cancer risk prediction in UK Biobank.验证 BOADICEA 模型在英国生物库中预测上皮性输卵管-卵巢癌风险的能力。
Br J Cancer. 2024 Nov;131(9):1473-1479. doi: 10.1038/s41416-024-02851-z. Epub 2024 Sep 18.
3
Enhancing the BOADICEA cancer risk prediction model to incorporate new data on , , updates to tumour pathology and cancer incidence.增强 BOADICEA 癌症风险预测模型,纳入新的数据、、更新的肿瘤病理学和癌症发病率数据。
J Med Genet. 2022 Dec;59(12):1206-1218. doi: 10.1136/jmedgenet-2022-108471. Epub 2022 Sep 26.
4
Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants.多基因风险评分与携带 BRCA1 和 BRCA2 致病性变异的个体的乳腺癌和上皮性卵巢癌风险。
Genet Med. 2020 Oct;22(10):1653-1666. doi: 10.1038/s41436-020-0862-x. Epub 2020 Jul 15.
5
BOADICEA: a comprehensive breast cancer risk prediction model incorporating genetic and nongenetic risk factors.BOADICEA:一种综合乳腺癌风险预测模型,纳入了遗传和非遗传风险因素。
Genet Med. 2019 Aug;21(8):1708-1718. doi: 10.1038/s41436-018-0406-9. Epub 2019 Jan 15.
6
Cost-effectiveness of Population-Based BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 Mutation Testing in Unselected General Population Women.基于人群的 BRCA1、BRCA2、RAD51C、RAD51D、BRIP1、PALB2 基因突变检测在未选择的普通人群女性中的成本效益。
J Natl Cancer Inst. 2018 Jul 1;110(7):714-725. doi: 10.1093/jnci/djx265.
7
Evaluation of polygenic risk scores for ovarian cancer risk prediction in a prospective cohort study.多基因风险评分在前瞻性队列研究中对卵巢癌风险预测的评估。
J Med Genet. 2018 Aug;55(8):546-554. doi: 10.1136/jmedgenet-2018-105313. Epub 2018 May 5.
8
Age of ovarian cancer diagnosis among BRIP1, RAD51C, and RAD51D mutation carriers identified through multi-gene panel testing.通过多基因panel 检测鉴定出 BRIP1、RAD51C 和 RAD51D 突变携带者的卵巢癌诊断年龄。
J Ovarian Res. 2021 Apr 29;14(1):61. doi: 10.1186/s13048-021-00809-w.
9
Cost-Effectiveness of Gene-Specific Prevention Strategies for Ovarian and Breast Cancer.卵巢癌和乳腺癌基因特异性预防策略的成本效益分析。
JAMA Netw Open. 2024 Feb 5;7(2):e2355324. doi: 10.1001/jamanetworkopen.2023.55324.
10
Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers.评估BRCA1和BRCA2突变携带者中用于乳腺癌和卵巢癌风险预测的多基因风险评分
J Natl Cancer Inst. 2017 Jul 1;109(7). doi: 10.1093/jnci/djw302.

引用本文的文献

1
Defining Lifetime Risk Thresholds for Breast Cancer Surgical Prevention.确定乳腺癌手术预防的终身风险阈值。
JAMA Oncol. 2025 Jul 24. doi: 10.1001/jamaoncol.2025.2203.
2
Progress and current trends in prediction models for the occurrence and prognosis of cancer and cancer-related complications: a bibliometric and visualization analysis.癌症及癌症相关并发症发生和预后预测模型的进展与当前趋势:文献计量与可视化分析
Front Oncol. 2025 Jul 8;15:1556521. doi: 10.3389/fonc.2025.1556521. eCollection 2025.
3
Adapting the BOADICEA breast and ovarian cancer risk models for the ethnically diverse UK population.

本文引用的文献

1
Comparative validation of the BOADICEA and Tyrer-Cuzick breast cancer risk models incorporating classical risk factors and polygenic risk in a population-based prospective cohort of women of European ancestry.基于欧洲血统女性的人群前瞻性队列中,纳入经典风险因素和多基因风险的 BOADICEA 和 Tyrer-Cuzick 乳腺癌风险模型的比较验证。
Breast Cancer Res. 2021 Feb 15;23(1):22. doi: 10.1186/s13058-021-01399-7.
2
Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants.多基因风险评分与携带 BRCA1 和 BRCA2 致病性变异的个体的乳腺癌和上皮性卵巢癌风险。
Genet Med. 2020 Oct;22(10):1653-1666. doi: 10.1038/s41436-020-0862-x. Epub 2020 Jul 15.
3
使BOADICEA乳腺癌和卵巢癌风险模型适用于种族多样化的英国人群。
Br J Cancer. 2025 Jul 17. doi: 10.1038/s41416-025-03117-y.
4
TEX10: A Novel Drug Target and Potential Therapeutic Direction for Sleep Apnea Syndrome.TEX10:睡眠呼吸暂停综合征的新型药物靶点及潜在治疗方向
Nat Sci Sleep. 2025 May 1;17:731-746. doi: 10.2147/NSS.S499895. eCollection 2025.
5
Transcriptome analysis of ovarian cancer uncovers association between tumor-related inflammation/immunity and patient outcome.卵巢癌的转录组分析揭示了肿瘤相关炎症/免疫与患者预后之间的关联。
Front Pharmacol. 2025 Feb 6;16:1500251. doi: 10.3389/fphar.2025.1500251. eCollection 2025.
6
Factors influencing role preferences in decision-making of healthy women with BRCA1/2 pathogenic variants: subanalysis from a randomised controlled decision coaching trial.影响携带BRCA1/2致病变异的健康女性决策中角色偏好的因素:一项随机对照决策指导试验的亚分析
BMC Cancer. 2025 Jan 28;25(1):164. doi: 10.1186/s12885-025-13541-1.
7
Validation of the BOADICEA model for epithelial tubo-ovarian cancer risk prediction in UK Biobank.验证 BOADICEA 模型在英国生物库中预测上皮性输卵管-卵巢癌风险的能力。
Br J Cancer. 2024 Nov;131(9):1473-1479. doi: 10.1038/s41416-024-02851-z. Epub 2024 Sep 18.
8
BOADICEA model: updates to the breast cancer risks for ages 60 years and older.BOADICEA模型:60岁及以上女性乳腺癌风险的更新
BJC Rep. 2024;2(1):53. doi: 10.1038/s44276-024-00079-1. Epub 2024 Jul 24.
9
The Associations and Causal Relationships of Ovarian Cancer - Construction of a Prediction Model.卵巢癌的关联与因果关系——预测模型的构建
Int J Womens Health. 2024 Jun 18;16:1127-1135. doi: 10.2147/IJWH.S462883. eCollection 2024.
10
Future implications of polygenic risk scores for life insurance underwriting.多基因风险评分对人寿保险承保的未来影响。
NPJ Genom Med. 2024 Mar 30;9(1):25. doi: 10.1038/s41525-024-00407-x.
Systematic review of acceptability, cardiovascular, neurological, bone health and HRT outcomes following risk reducing surgery in BRCA carriers.
BRCA 携带者行降低风险手术后的可接受性、心血管、神经、骨骼健康和激素替代疗法结局的系统评价。
Best Pract Res Clin Obstet Gynaecol. 2020 May;65:46-65. doi: 10.1016/j.bpobgyn.2020.01.006. Epub 2020 Feb 4.
4
Ovarian and Breast Cancer Risks Associated With Pathogenic Variants in RAD51C and RAD51D.RAD51C 和 RAD51D 种系致病变异与卵巢癌和乳腺癌风险相关。
J Natl Cancer Inst. 2020 Dec 14;112(12):1242-1250. doi: 10.1093/jnci/djaa030.
5
iCARE: An R package to build, validate and apply absolute risk models.iCARE:用于构建、验证和应用绝对风险模型的 R 包。
PLoS One. 2020 Feb 5;15(2):e0228198. doi: 10.1371/journal.pone.0228198. eCollection 2020.
6
Cancer Risks Associated With Germline Pathogenic Variants: An International Study of 524 Families.与生殖系致病性变异相关的癌症风险:一项对524个家庭的国际研究。
J Clin Oncol. 2020 Mar 1;38(7):674-685. doi: 10.1200/JCO.19.01907. Epub 2019 Dec 16.
7
Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the Prospective Lynch Syndrome Database.6350 名致病性错配修复变异携带者的基因、年龄和性别与癌症风险:来自前瞻性 Lynch 综合征数据库的研究结果。
Genet Med. 2020 Jan;22(1):15-25. doi: 10.1038/s41436-019-0596-9. Epub 2019 Jul 24.
8
10-year performance of four models of breast cancer risk: a validation study.四种乳腺癌风险模型的 10 年表现:一项验证研究。
Lancet Oncol. 2019 Apr;20(4):504-517. doi: 10.1016/S1470-2045(18)30902-1. Epub 2019 Feb 21.
9
BOADICEA: a comprehensive breast cancer risk prediction model incorporating genetic and nongenetic risk factors.BOADICEA:一种综合乳腺癌风险预测模型,纳入了遗传和非遗传风险因素。
Genet Med. 2019 Aug;21(8):1708-1718. doi: 10.1038/s41436-018-0406-9. Epub 2019 Jan 15.
10
Evaluation of polygenic risk scores for ovarian cancer risk prediction in a prospective cohort study.多基因风险评分在前瞻性队列研究中对卵巢癌风险预测的评估。
J Med Genet. 2018 Aug;55(8):546-554. doi: 10.1136/jmedgenet-2018-105313. Epub 2018 May 5.